Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy

被引:90
作者
Feng, Mary
Hanlon, Alexandra L.
Pisansky, Thomas M.
Kljban, Deborah
Cation, Charles N.
Michalski, Jeff M.
Zelefsky, Michael J.
Kupelian, Patrick A.
Pollack, Alan
Kestin, Larry L.
Valicenti, Richard K.
DeWeese, Theodore L.
Sandler, Howard M.
机构
[1] Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[2] Temple Univ, Dept Publ Hlth, Philadelphia, PA 19122 USA
[3] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[5] Univ Toronto, Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON, Canada
[6] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Dept Radiat Oncol, St Louis, MO USA
[7] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA
[8] MD Anderson Canc Ctr, Dept Radiat Oncol, Orlando, FL USA
[9] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[10] William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48072 USA
[11] Thomas Jefferson Univ, Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19107 USA
[12] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21218 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 68卷 / 05期
关键词
prostate cancer; radiation; adjuvant; salvage; toxicity;
D O I
10.1016/j.ijrobp.2007.01.049
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities. Methods and Materials: A large multi-institutional database that included 959 men who received postoperative RT after radical prost-atectomy (RP) was analyzed: 19 % received adjuvant RT, 81 % received salvage RT, 78 % were treated to the prostate bed only, and 22% received radiation to the pelvis. Results: The median follow-up time was 55 months. At 5 years, 10% of patients had Grade 2 late GU toxicity and 1 % had Grade 3 late GU toxicity, while 4% of patients had Grade 2 late GI toxicity and 0.4% had Grade 3 late GI toxicity. Multivariate analysis demonstrated that adjuvant RT (p = 0.03), androgen deprivation (p < 0.0001), and prostate bed-only RT (p = 0.007) predicted for Grade 2 or higher late GU toxicity. For GI toxicity, although adjuvant RT was significant in the uni,variate analysis, no significant factors were found in the multivariate analysis. Conclusions: Overall, the number of high-grade toxicities for postoperative RT was low. Therefore, adjuvant and salvage RT can safely be used in the appropriate settings. (C) 2007 Elsevier
引用
收藏
页码:1417 / 1423
页数:7
相关论文
共 26 条
[1]   MULTIVARIATE-ANALYSIS OF FACTORS PREDICTING LOCAL RELAPSE AFTER RADICAL PROSTATECTOMY - POSSIBLE INDICATIONS FOR POSTOPERATIVE RADIOTHERAPY [J].
ANSCHER, MS ;
PROSNITZ, LR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (04) :941-947
[2]  
Bolla M., 2002, International Journal of Radiation Oncology Biology Physics, V54, P62, DOI 10.1016/S0360-3016(02)03164-4
[3]   Post-operative radiotherapy (P-RXT) after radical prostatectorny (Px) improves progression-free survival (PFS) in pT3NO prostate cancer (PC) (EORTC 22911) [J].
Bolla, M ;
Van Poppel, H ;
Van Cangh, P ;
Vekemans, K ;
Rigatti, P ;
Haustermans, K ;
Bulens, P ;
Villa, E ;
Collette, L .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01) :S186-S186
[4]   Postoperative radiotherapy after radical prostatectomy:: a randomised controlled trial (EORTC trial 22911) [J].
Bolla, M ;
van Poppel, H ;
Collette, L ;
van Cangh, P ;
Vekemans, K ;
Da Pozzo, L ;
de Reijke, TM ;
Verbaeys, A ;
Bosset, JF ;
van Velthoven, R ;
Maréchal, JM ;
Scalliet, P ;
Haustermans, K ;
Piérart, M .
LANCET, 2005, 366 (9485) :572-578
[5]   Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy [J].
Lange, PH .
JOURNAL OF UROLOGY, 1998, 159 (01) :177-178
[6]  
Cox JD, 1999, J CLIN ONCOL, V17, P1155
[7]   Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy [J].
Formenti, SC ;
Lieskovsky, G ;
Simoneau, AR ;
Skinner, D ;
Groshen, S ;
Chen, SC ;
Petrovich, Z .
JOURNAL OF UROLOGY, 1996, 155 (02) :616-619
[8]   Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy [J].
Formenti, SC ;
Lieskovsky, G ;
Skinner, D ;
Tsao-Wei, DD ;
Groshen, S ;
Petrovich, Z .
UROLOGY, 2000, 56 (03) :453-458
[9]   Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02 [J].
Hanks, GE ;
Pajak, TF ;
Porter, A ;
Grignon, D ;
Brereton, H ;
Venkatesan, V ;
Horwitz, EM ;
Lawton, C ;
Rosenthal, SA ;
Sandler, HM ;
Shipley, WU .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3972-3978
[10]   Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer [J].
Kupelian, P ;
Katcher, J ;
Levin, H ;
Zippe, C ;
Klein, E .
UROLOGY, 1996, 48 (02) :249-260